GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (OTCPK:KHTRF) » Definitions » Other Operating Expense

Knight Therapeutics (Knight Therapeutics) Other Operating Expense : $33.3 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Other Operating Expense?

Knight Therapeutics's Other Operating Expense for the three months ended in Mar. 2024 was $8.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $33.3 Mil.

Knight Therapeutics's quarterly Other Operating Expense declined from Sep. 2023 ($8.5 Mil) to Dec. 2023 ($8.3 Mil) and declined from Dec. 2023 ($8.3 Mil) to Mar. 2024 ($8.0 Mil).

Knight Therapeutics's annual Other Operating Expense increased from Dec. 2021 ($32.2 Mil) to Dec. 2022 ($38.1 Mil) but then declined from Dec. 2022 ($38.1 Mil) to Dec. 2023 ($33.6 Mil).


Knight Therapeutics Other Operating Expense Historical Data

The historical data trend for Knight Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Other Operating Expense Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 19.93 32.17 38.09 33.57

Knight Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.16 8.49 8.48 8.29 8.03

Knight Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (Knight Therapeutics) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.